In this week’s Pointers with Dr Portela, the 208SkinDoc talks a case of a man who received a chemical peel that went wrong.

In this week’s Pointers with Dr Portela, the 208SkinDoc talks about the end of Melanoma Awareness Month and gives advice on how to prevent skin cancer.

Joshua Zeichner, MD, discusses how important it is to treat acne properly and gives a tip about moisturizers and topical retinoids.

Darrell S. Rigel, MD, MS, FAAD, answers the question of what is up coming in the world of dermatology in the way of precision medicine.

In a video with Dermatology Times®, James Q. Del Rosso, DO, discusses his presentation “What’s News in the Medicine Chest” at the current 2022 Fall Clinical Dermatology Conference for PAs & NPs.

Will drinking caffeinated coffee reduce skin cancer risk? Is gene expression profiling set to become mainstream testing for melanoma? See what Darrell S. Rigel, MD, MS, FAAD, has to say.

Darrell S. Rigel highlights what to expect for the 2022 Fall Clinical Dermatology Conference for PAs & NPs happening June 3 to 5 in Scottsdale, Arizona.

In this drug pipeline interview, Christopher Bunick, MD, PhD, discusses what is innovative in future acne treatment options, what research is happening, and what potential approvals the dermatology space has to look forward to.

In this week’s Pointers with Dr Portela, the 208SkinDoc dives into the reason why his channel exists and how he plans to help the average patient watching his YouTube videos.

In this week’s Pointers with Dr Portela, the 208SkinDoc hosts a podcast called, “Between Two Derms.” This week he covers cases in the clinic, psoriasis at the Met Gala and more.

In this week’s Pointers with Dr Portela, the 208SkinDoc has posted several YouTube shorts on sunscreen. See what pearls he had to share on protecting skin from the sun.

Among other things, it is about what happens before the scalpel that Ann W. Silk, MD, MS would like to see more research into advanced BCC treatment. Neoadjuvant therapies show promise in helping patients avoid or downgrade surgery, as she explains here. Silk also delves into other areas of research that offer new potential for treating advanced BCC.

Is timing everything? Chrysalyne D. Schmults, MD, FAAD looks to a future where clinicians have a better understanding of the “how” and “when” of using hedgehog inhibitors and anti-PD1 medication. Here are the questions she’d like to see answered in upcoming research.

Darrell S. Rigel, MD, MS, FAAD vision of the future treatment innovations for would include medications based on better-targeted immune pathways, effective ways to treat metastatic BCC, and a vaccine to prevent advanced BCC from developing. Rigel addresses these and other developments he sees or would like to see on the horizon.

In the world of medical oncologist Ann W. Silk, MD, MS a 30% response rate can be good news. So can drugs that can limit side effects to address a discontinuation rate that may be as high as 30%. Silk discusses the mechanisms of action of existing and new tools, such as immunotherapy, and recommendations for how physicians can maximize their effectiveness in a clinical setting.

Chrysalyne D. Schmults, MD, provides talking points on assessing which patients are ideal candidates for surgery and, when surgery is not an option, matching medications to the needs and quality of life concerns for the individual patient. She offers best-practice guidance for optimizing treatment choices that address challenges surrounding extended durability, reduction of adverse effects, and improvement in rates of occurrence of progression.

Darrell S. Rigel, MD, talks through the pros, cons, and unknowns of established medications such as Hedgehog inhibitors and newly FDA-approved drugs such as cemiplimab (Libtayo; Sanofi and Regeneron Pharmaceuticals). Get the latest on dosing, drug holidays, tolerability, and long-term disease management.

What risks do patients with the highest stage advanced BCC have for metastasis or death? Chrysalyne D. Schmults, MD, and her team at Brigham and Women’s Hospital in Boston, Massachusetts, developed a new staging system to help answer that question. Here, she shares insights on tumor classification, its implication for treatment, and the ground rules for creating an effective tumor review board.

By the time patients present to Darrell S. Rigel, MD, with advanced basal cell carcinoma (BCC), their lesions are likely to be too large or too numerous to be curable with a simple surgical solution. “You get to a point where there are just positive margins or the lesion is so large that it’s going to require inpatient treatment,” he says. “Because of the complexity, it’s important to build a multidisciplinary team to assess the patient, create a treatment plan, and optimize ongoing management.” Find out how to build a strong team and what each member can contribute.

Is rosacea being confused with acne? Are physicians treating the their patients with the patient's expectations in mind? Questions like these are more are answered by Adebola Dele-Michael, MD.